As FDA Set To Make Biosimilar Decision; Sandoz's Market Date, Cost Unclear

FDA could decide on the first U.S. biosimilar -- Sandoz's biosimilar of Amgen's Neupogen -- as soon as Sunday (March 8), but the expected approval doesn't mean the product will be available anytime soon or even be less expensive than the brand product, court documents indicate. Sandoz is fighting in court to stop Amgen's bid to delay marketing of the biosimilar filgrastim by as long as 400 days, and although Sandoz hopes to convince the court that the brand company's...